

## Confirmed Speakers

### Plenary Lectures

#### Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery



Prof. Chas BOUNTRA  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

#### IUPAC Richter Prize Lecture Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D



Dr Helmut BUSCHMANN  
(PHARMA CONSULTING AACHEN, Aachen, Germany)

#### The UCB-Ehrlich Award for Excellence in Medicinal Chemistry Small Molecule Control Of Intracellular Protein Levels



Prof. Craig CREWS  
(YALE UNIVERSITY, New Haven, United States)

#### Portugal: the Right Place to build Partnerships in Health



Dr Joaquim CUNHA  
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

#### The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery Thermodynamics Assisted Drug Discovery



Dr György G. FERENCZY  
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)



Prof. Gyorgy KESERU  
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

### Plenary Lecture



Dr Sabine HADIDA  
(VERTEX PHARMACEUTICALS, San Diego, United States)

#### The Nauta Award for Pharmacochemistry Pursuing Compound Quality



Dr Paul LEESON  
(GLAXOSMITHKLINE, United Kingdom)

#### High Resolution Mass Spectrometry in Clinical Proteomics

## Confirmed Speakers



Prof. Dr Matthias MANN  
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)

### Innovation Through Chemistry at the Interfaces of the Scientific Disciplines

Dr Martin MISSBACH  
(NOVARTIS, Basel, Switzerland)

### Partnership between Public and Private Sources: Pharma and IMI Perspective



Dr Paul Peter TAK  
(EFPIA, Brentford, United Kingdom)

### Plenary Lecture



Prof. Hans WESTERHOFF  
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

## Invited Speakers

### Targeting Spore Germination to Prevent Clostridium Difficile Infections



Dr Ernesto ABEL-SANTOS  
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)

### Cyclic Peptides from the nature to the synthetic ones



Prof. Fernando ALBERICIO  
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

### Sponging Off Nature for New Drug Leads



Prof. Raymond ANDERSEN  
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

### Omarigliptin: A Once-weekly Oral Antidiabetic Agent



Dr Tesfaye BIFTU  
(MERCK, Rahway, United States)

### Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging



Dr Sam BONACORSI  
(BRISTOL-MYERS SQUIBB, Princeton, United States)

### Invited Lecture

## Confirmed Speakers



Dr Terry BOWLIN  
(MICROBIOTIX, Worcester, United States)

### Being More Certain About Uncertainty In Computational Toxicology Modeling



Dr Scott BOYER  
(KAROLINSKA INSTITUTET, Södertälje, Sweden)

### Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites



Prof. Reto BRUN  
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

### Recent Advances In Asymmetric Catalysis



Prof. Erick M. CARREIRA  
(ETH ZÜRICH, Zürich, Switzerland)

### Inflammation, Obesity and Metabolic Disease



Dr Ajay CHAWLA  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

### Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter



Dr Chris CHIPOT  
(UNIVERSITY OF ILLINOIS, Urbana, United States)

### Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?



Dr Clara CHRIST  
(BAYER PHARMA, Berlin, Germany)

### Functional and Structural Insights into GPCR Allostery



Prof. Arthur CHRISTOPOULOS  
(MONASH UNIVERSITY, Parkville, Australia)

### BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction



Prof. Stuart CONWAY  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

### New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids

## Confirmed Speakers



Prof. Pier Giorgio COZZI  
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

### Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors



Prof. Helena DANIELSON  
(UPPSALA UNIVERSITY, Uppsala, Sweden)

### Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.



Prof. Iwan DE ESCH  
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

### Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors



Dr Maria Emilia DI FRANCESCO  
(UTMD ANDERSON CANCER CENTER, Houston, United States)

### Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target



Prof. Stephen DOUTHWAITE  
(UNIVERSITY OF SOUTHERN DENMARK, Odensen, Denmark)

### A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development



Dr Chad ELMORE  
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

### Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins



Prof. Paul FISH  
(UCL SCHOOL OF PHARMACY, London, United Kingdom)

### Experiences with Natural Product Total Synthesis



Prof. Alois FÜRSTNER  
(MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

### Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box



Dr Francisco-Javier GAMO  
(GLAXOSMITHKLINE, Madrid, Spain)

### CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study

## Confirmed Speakers



Dr Gerard GIBLIN  
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

### Mechanism-Based Prediction of Drug-Induced Liver Injury



Dr Christopher GOLDRING  
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

### Integration of New Chemical Diversity and Design Approaches in Lead Generation



Dr Timothy GRESE  
(ELI LILLY AND COMPANY, Indianapolis, United States)

### CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis



Dr Uwe GREThER  
(F. HOFFMANN-LA-ROCHE, Basel, Switzerland)

### Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function



Prof. Helmut GRUBMÜLLER  
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

### An Introduction To Ion Channels As Drug Targets



Prof. Morten GRUNNET  
(LUNDBECK, Valby, Denmark)

### MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application



Prof. Christian HEINIS  
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

### Discovery of the mGlu5 Negative Allosteric Modulator RO4917523



Dr Georg JAESCHKE  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

### Development of New Anti-Infective Agents and a Novel Delivery Strategy



Prof. Reuben JIH-RU HWU  
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

### Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds

## Confirmed Speakers



Prof. Han-Young KANG  
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

### Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya



Prof. Anake KIJOA  
(UNIVERSITY OF PORTO, Porto, Portugal)

### Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing



Dr Jesper LAU  
(NOVO NORDISK, Maaloev, Denmark)

### Translational Modeling in Support to Discovery and Early Development



Dr Thierry LAVE  
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

### Pain-relieving Peptides Targeting Acid-Sensing Ion Channels



Dr Eric LINGUEGLIA  
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

### Novel Anti-Cancer Treatment Targeting Vps34



Dr Jessica MARTINSSON  
(SPRINT BIOSCIENCE, Stockholm, Sweden)

### High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies



Dr. Jonathan MASON  
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

### Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721



Dr Dustin James MERGOTT  
(ELI LILLY, Indianapolis, United States)

### The Impact of Polypharmacology on Lead Generation



Prof. Jordi MESTRES  
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)

### Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer

## Confirmed Speakers



Prof. Filippo MINUTOLO  
(UNIVERSITY OF PISA, Pisa, Italy)

### **Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry**



Dr Marc MOSRIN  
(BAYER CROPSOURCE AG, Frankfurt am Main, Germany)

### **Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics**



Dr Daniel OBRECHT  
(POLYPHOR, Allschwil, Switzerland)

### **A First In Class Chemical Probe For Family VIII Bromodomains**



Dr Dafydd OWEN  
(PFIZER, Cambridge, United States)

### **Novel Boron-containing Anti-infective Agents**



Dr Jacob PLATTNER  
(ANACOR PHARMACEUTICALS, Palo Alto, United States)

### **Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect**



Dr Hasane RATNI  
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

### **Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery**



Dr Adam RENSLO  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

### **Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development**



Dr Esther SCHMITT  
(NOVARTIS, Basel, Switzerland)

### **PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery**



Dr Peter J.H. SCOTT  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

## Confirmed Speakers

### The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design



Dr Moran SHALEV BEN AMI  
(WEIZMANN INSTITUTE, Rehovot, Israel)

### New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds



Prof. Artur M.S. SILVA  
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

### Discovery and Development of Surotomycin for the Treatment of C. difficile



Dr Jared SILVERMAN  
(CUBIST PHARMACEUTICALS, Lexington, United States)

### CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson's Disease



Prof. Rick SILVERMAN  
(NORTHWESTERN UNIVERSITY, Evanston, United States)

### Fragment-Based Discovery of BACE Inhibitors for Alzheimer's Disease



Dr Andrew STAMFORD  
(MERCK RESEARCH LABORATORIES, Rahway, United States)

### Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs



Prof. Jan STEYAERT  
(VUB, Brussels, Belgium)

### 1,1'-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors



Dr Thomas TRIESELMANN  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

### Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites



Prof. Nico VERMEULEN  
(VU UNIVERSITY, Amsterdam, The Netherlands)

### Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells

Dr Jörg VOLLMER  
(NEXIGEN, Cologne, Germany)

### Medicinal Chemistry Optimisation Of Binding Kinetics



## Confirmed Speakers



Prof. Mike WARING  
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

### Fast and Safe Synthesis of Pharmaceutically Relevant Molecules



Prof. Thomas WIRTH  
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

### Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation



Dr Steve WOODHEAD  
(TAKEDA CALIFORNIA, San Diego, United States)

## Oral Communications

### Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists



Assoc. Prof. Marko ANDERLUH  
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

### Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?



Dr Alexandra ANTUNES  
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

### Interrogation the Bromodomain Family through Chemical Biology



Dr Steve BELLON  
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

### A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement

Mr Alban BUJARD  
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

### The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma



Dr Rhona COX  
(ASTRAZENECA, Mölndal, Sweden)

### CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization



Dr Maurizio DELCANALE  
(CHIESI, Parma, Italy)

## Confirmed Speakers

### Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors



Dr Erin DIMAURO  
(AMGEN, Cambridge, United States)

### Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents



Dr Martin EMPTING  
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

### P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies



Mr Ricardo FERREIRA  
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

### Covalent Agonists Facilitating Crystallisation of GPCRs



Prof. Peter GMEINER  
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

### CRTH2: Can Residence Time Help?



Dr Elena GOMEZ  
(ALMIRALL, BARCELONA, Spain)

### Discovery of Ivacaftor (Vx-770), a Cfr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients



Dr Sabine HADIDA  
(VERTEX PHARMACEUTICALS, San Diego, United States)

### Discovery of the First and Only Small Molecule II-17 Blockers



Dr Nils HANSEN  
(VIPERGEN, Copenhagen, Denmark)

### Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD



Dr Adam HUGHES  
(THERAVANCE INC., South San Francisco, United States)

### The Discovery of APD334, a Selective S1P1 Functional Antagonist

## Confirmed Speakers



Dr Robert JONES  
(ARENA PHARM, SAN DIEGO, United States)

### **Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232**



Dr Stefanie KRAMER  
(ETH ZÜRICH, Zürich, Switzerland)

### **Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer**



Dr Martyna KRZYKAWSKA-SERDA  
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

### **Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease**



Dr Christopher LUCKHURST  
(BIOFOCUS, Saffron Walden, United Kingdom)

### **Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies**



Prof. Ana MARTINEZ  
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

### **Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a**



Dr Michael MICHAELIDES  
(ABBVIE, North Chicago, United States)

### **Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases**



Prof. Marko D. MIHOVILOVIC  
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

### **Development of Novel Building Blocks to Accelerate Drug Discovery**



Dr Pavel MYKHAILIUK  
(ENAMINE, Kyiv, Ukraine)

### **Discovery of Small Molecule Ror? Modulators for the Treatment of Autoimmune Diseases**

## Confirmed Speakers



Dr Frank NARJES  
(ASTRAZENECA, Mölndal, Sweden)

### Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism



Dr Anneli NORDQVIST  
(ASTRAZENECA, Mölndal, Sweden)

### The Evolution of an in vivo Efficacious Bace1 Inhibitor



Dr Daniel OEHLRICH  
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

### EFMC Prize for a Young Medicinal Chemist in Academia Inhibitors and Substrates of the Human Lysine Deacylase Enzymes



Prof. Christian A. OLSEN  
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

### Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)



Dr Philippe PANCHAUD  
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

### EFMC Prize for a Young Medicinal Chemist in Industry Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC



Dr Grazia PIZZI  
(NOVARTIS PHARMA, Basel, Switzerland)

### Identifying Selective Inhibitors of FGFR4 Kinase



Dr Kurt PIKE  
(ASTRAZENECA, Cambridge, United Kingdom)

### Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening



Dr David RODRIGUEZ DIAZ  
(STOCKHOLM UNIVERSITY, Solna, Sweden)

### From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein

## Confirmed Speakers



Dr Fanny ROUSSI  
(ICSN - CNRS, Gif sur Yvette, France)

### **Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies**



Dr Wolfgang SCHWEDE  
(BAYER, Berlin, Germany)

### **Cebranopadol, a Novel, Potent Analgesic**



Dr Henning STEINHAGEN  
(GRÜNENTHAL, Verona, Italy)

### **Novel Potent Inhibitors of the Histone Demethylase KDM1A**



Dr Paola VIANELLO  
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

### **Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases**



Dr Franz VON NUSSBAUM  
(BAYER PHARMA, Lyon, France)

### **Antibodies as Tools to Enable Small Molecule Drug Discovery**



Dr Marta WESTWOOD  
(UCB, Slough, United Kingdom)

### **Improving Physicochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei**



Prof. Jennifer WOODRING  
(NORTHEASTERN UNIVERSITY, Boston, United States)

### **Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate**



Dr Olga ZUBKOVA  
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)